Janus Capital Management LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 2.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,723,692 shares of the company’s stock after acquiring an additional 237,619 shares during the quarter. Janus Capital Management LLC owned approximately 0.83% of Eli Lilly and worth $733,731,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also bought and sold shares of LLY. Heritage Trust Co acquired a new position in Eli Lilly and during the first quarter worth $135,000. Penserra Capital Management LLC boosted its holdings in Eli Lilly and by 9.5% during the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after acquiring an additional 176 shares during the period. Crestwood Advisors Group LLC bought a new stake in shares of Eli Lilly and in the first quarter valued at about $179,000. Sandy Spring Bank lifted its stake in shares of Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after buying an additional 750 shares during the period. Finally, Coldstream Capital Management Inc. bought a new stake in shares of Eli Lilly and in the first quarter valued at about $200,000. 75.77% of the stock is currently owned by hedge funds and other institutional investors.
In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the sale, the insider now directly owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 825,000 shares of company stock valued at $68,456,650. 0.20% of the stock is owned by corporate insiders.
A number of research analysts have commented on LLY shares. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating and issued a $93.00 price target on shares of Eli Lilly and in a report on Thursday, June 22nd. Deutsche Bank AG reaffirmed a “buy” rating and issued a $91.00 price objective (up from $90.00) on shares of Eli Lilly and in a research note on Monday, July 17th. Morgan Stanley reaffirmed a “hold” rating and issued a $86.00 price objective on shares of Eli Lilly and in a research note on Friday. Finally, Berenberg Bank reissued a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research report on Thursday, July 27th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus target price of $88.27.
Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.76% during trading on Friday, reaching $82.44. 5,374,504 shares of the company’s stock traded hands. The company has a market cap of $86.97 billion, a price-to-earnings ratio of 35.67 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The company’s 50-day moving average is $80.89 and its 200 day moving average is $82.06.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company’s revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm posted $0.86 EPS. Equities analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were given a $0.52 dividend. The ex-dividend date of this dividend was Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. Eli Lilly and’s dividend payout ratio is presently 90.04%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.